T1	Qualifier 28 34	active
T2	Condition 35 38	CSC
R1	Has_qualifier Arg1:T2 Arg2:T1	
T3	Procedure 13 23	treatments
R2	AND Arg1:T3 Arg2:T2	
T4	Temporal 4 12	previous
R3	Has_temporal Arg1:T3 Arg2:T4	
T5	Temporal 41 49	Previous
T6	Drug 66 104	mineralocorticoid receptor antagonists
T7	Condition 110 114	cCSC
T8	Condition 122 136	other diseases
*	OR T7 T8
T9	Scope 110 136	cCSC or for other diseases
R4	Has_scope Arg1:T6 Arg2:T9	
R5	Has_temporal Arg1:T6 Arg2:T5	
T10	Drug 162 177	corticosteroids
T11	Temporal 139 146	Current
R6	Has_temporal Arg1:T10 Arg2:T11	
T12	Qualifier 179 186	topical
T13	Qualifier 190 198	systemic
T14	Scope 179 198	topical or systemic
R7	Has_scope Arg1:T10 Arg2:T14	
T15	Procedure 201 219	corticosteroid use
T16	Temporal 220 276	within 3 months before possible start of trial treatment
T17	Reference_point 243 276	possible start of trial treatment
R8	Has_index Arg1:T16 Arg2:T17	
T18	Procedure 302 326	corticosteroid treatment
T19	Temporal 327 386	within the first 2 years from the start of the trial period
T20	Reference_point 334 386	the first 2 years from the start of the trial period
R9	Has_index Arg1:T19 Arg2:T20	
T21	Mood 281 292	anticipated
R10	Has_mood Arg1:T18 Arg2:T21	
R11	Has_temporal Arg1:T18 Arg2:T19	
R12	Has_temporal Arg1:T15 Arg2:T16	
*	OR T10 T15 T18
T22	Non-representable 389 462	Evidence of another diagnosis that can explain serous SRF or visual loss;
T23	Measurement 464 492	Best-corrected visual acuity
T24	Value 493 501	< 20/200
R13	Has_value Arg1:T23 Arg2:T24	
T25	Qualifier 525 533	Profound
T26	Condition 534 555	chorioretinal atrophy
R14	Has_qualifier Arg1:T26 Arg2:T25	
T27	Qualifier 559 579	central macular area
R15	Has_qualifier Arg1:T26 Arg2:T27	
T28	Procedure 583 597	ophthalmoscopy
T29	Procedure 602 605	OCT
T30	Scope 583 605	ophthalmoscopy and OCT
R16	AND Arg1:T30 Arg2:T26	
T31	Measurement 608 614	Myopia
T32	Value 615 619	> 6D
R17	Has_value Arg1:T31 Arg2:T32	
T33	Condition 622 633	Visual loss
T34	Condition 641 658	serous detachment
T35	Procedure 662 665	OCT
T36	Temporal 666 675	< 6 weeks
*	OR T34 T33
T37	Scope 622 658	Visual loss and/or serous detachment
R18	Has_scope Arg1:T35 Arg2:T37	
R19	Has_temporal Arg1:T35 Arg2:T36	
T38	Qualifier 678 688	Continuous
T39	Qualifier 696 707	progressive
T40	Condition 708 719	visual loss
*	OR T39 T38
T41	Scope 678 707	Continuous and/or progressive
R20	Has_scope Arg1:T40 Arg2:T41	
T42	Temporal 720 731	> 18 months
T43	Condition 735 752	serous detachment
T44	Procedure 756 759	OCT
T45	Temporal 760 771	> 18 months
R21	Has_temporal Arg1:T44 Arg2:T45	
R22	Has_temporal Arg1:T40 Arg2:T42	
R23	AND Arg1:T44 Arg2:T43	
*	OR T44 T40
T46	Measurement 798 802	ICGA
T47	Value 777 794	hyperfluorescence
T48	Negation 774 776	No
R24	Has_negation Arg1:T47 Arg2:T48	
R25	Has_value Arg1:T46 Arg2:T47	
T49	Condition 805 823	Intraretinal edema
T50	Procedure 827 830	OCT
R26	AND Arg1:T50 Arg2:T49	
T51	Condition 844 861	Contraindications
T52	Procedure 866 868	FA
T53	Procedure 872 876	ICGA
*	OR T52 T53
T54	Scope 866 876	FA or ICGA
R27	Has_scope Arg1:T51 Arg2:T54	
T55	Condition 890 907	Contraindications
T56	Procedure 912 934	photodynamic treatment
T57	Condition 936 945	pregnancy
T58	Condition 947 956	porphyria
T59	Qualifier 958 966	severely
T60	Condition 967 991	disturbed liver function
R28	Has_qualifier Arg1:T60 Arg2:T59	
*	OR T57 T58 T60
T61	Scope 936 991	pregnancy, porphyria, severely disturbed liver function
R29	AND Arg1:T55 Arg2:T56	
T62	Scope 890 934	Contraindications for photodynamic treatment
R30	Subsumes Arg1:T62 Arg2:T61	
T63	Non-representable 994 1120	Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening
T64	Condition 1139 1156	contraindications
T65	Drug 1175 1185	eplerenone
T66	Condition 1197 1209	hyperkalemia
T67	Condition 1211 1235	abnormal renal clearance
T68	Measurement 1220 1235	renal clearance
T69	Value 1211 1219	abnormal
R31	Has_value Arg1:T68 Arg2:T69	
T70	Condition 1237 1265	severe hepatic insufficiency
T71	Measurement 1267 1277	Child-Pugh
T72	Value 1278 1279	C
R32	Has_value Arg1:T71 Arg2:T72	
R33	AND Arg1:T64 Arg2:T65	
*	OR T66 T68 T70 T75 T83
R34	multi Arg1:T68 Arg2:T67	
R35	Subsumes Arg1:T70 Arg2:T71	
T73	Condition 1282 1306	type 2 diabetes mellitus
T74	Condition 1312 1328	microalbuminuria
T75	Scope 1282 1328	type 2 diabetes mellitus with microalbuminuria
T76	Temporal 1330 1341	concomitant
T77	Drug 1349 1370	potassium supplements
T78	Drug 1372 1399	potassium-sparing diuretics
T79	Drug 1401 1425	strong CYP3A4 inhibitors
T80	Drug 1452 1465	ACE-inhibitor
T81	Drug 1473 1508	angiotensin receptor blocking agent
T82	Scope 1452 1508	ACE-inhibitor and an angiotensin receptor blocking agent
*	OR T77 T78 T79 T82
T83	Scope 1349 1508	potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent
R36	Has_temporal Arg1:T83 Arg2:T76	
T84	Non-representable 1511 1638	Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;
T85	Condition 1640 1651	Soft drusen
T86	Qualifier 1655 1666	treated eye
T87	Qualifier 1670 1680	fellow eye
*	OR T86 T87
T88	Scope 1655 1680	treated eye or fellow eye
T89	Condition 1691 1719	choroidal neovascularization
T90	Procedure 1723 1737	ophthalmoscopy
R38	Has_scope Arg1:T85 Arg2:T88	
T91	Procedure 1745 1747	FA
T92	Procedure 1748 1752	ICGA
T93	Qualifier 1760 1769	study eye
T94	Scope 1723 1752	ophthalmoscopy and/or FA/ICGA
*	OR T90 T91 T92
R37	AND Arg1:T94 Arg2:T89	
R39	Has_qualifier Arg1:T94 Arg2:T93	
*	OR T85 T94
